Business
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer
GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the appointment of Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell, the Company's Controller, who had assumed CFO responsibilities at the Company on an interim basis in November 2025
About this update from Beyond Air, Inc.
[{"type":"image","alt":"Beyond Air™","displaySize":"","headline":null,"caption":"Beyond Air™","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/283e6374c7eeb2f53ca652917eb5334d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cVMIN3hdiWRLf4negBQkjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/283e6374c7eeb2f53ca652917eb5334d","width":264,"height":50}},"lazy":false},{"type":"text","content":"GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the appointment of Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell, the Company's Controller, who had assumed CFO responsibilities at the Company on an interim basis in November 2025, will resume his prior role as of that date.","length":549,"tagName":"p"},{"type":"text","content":""It is a pleasure to welcome Dan to the Beyond Air team,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “He brings a strong track record of guiding companies through significant growth and developing high-performing finance organizations that can support commercial scale. I look forward to leveraging his experience as we continue advancing our strategy and build a market-leading company.”","length":419,"tagName":"p"},{"type":"text","content":"“I am honored to join the Beyond Air team at such a pivotal moment in the Company’s evolution. As market awareness continues to build around LungFit PH and the team prepares for the highly anticipated FDA approval of the second generation LungFit PH and subsequent commercial launch, I look forward to working closely with the leadership team to ensure strong financial stewardship and support the successful execution of our commercial strategy,” stated Mr. Moorhead.","length":468,"tagName":"p"},{"type":"text","content":"Mr. Moorhead brings more than 20 years of finance leadership experience across both public and private companies. From June 2017 to August 2025, he served as Chief Financial Officer of Zynex, Inc., a publicly traded, commercial-stage medical dev...